Neovasc Inc. Capex to Sales

Capex to Sales of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capex to Sales growth rates and interactive chart.


Highlights and Quick Summary

  • Capex to Sales for the quarter ending March 31, 2022 was 0.0 (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Capex to Sales decreased by -100.0%
  • Annual Capex to Sales for 2021 was 0.07 (a -60.5% decrease from previous year)
  • Annual Capex to Sales for 2020 was 0.17 (a 45.0% increase from previous year)
  • Annual Capex to Sales for 2019 was 0.11 (a -128.15% decrease from previous year)
  • Twelve month Capex to Sales ending March 31, 2022 was 0.0 (a -100.0% decrease compared to previous quarter)
  • Twelve month trailing Capex to Sales decreased by -100.0% year-over-year
Trailing Capex to Sales for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
0.0 0.06 0.09 0.2
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capex to Sales of Neovasc Inc.

Most recent Capex to Salesof NVCN including historical data for past 10 years.

Interactive Chart of Capex to Sales of Neovasc Inc.

Neovasc Inc. Capex to Sales for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.0
2021 0.02 0.0 0.17 0.09 0.07
2020 0.14 0.36 0.02 0.08 0.17
2019 0.14 0.11 0.14 0.08 0.11
2018 0.05 0.26 -2.11 0.09 -0.41
2017 0.05 0.04 0.09 0.19 0.09
2016 -24.49 0.01 0.13 0.15 -7.05
2015 0.22 0.16 0.3 0.17 0.22
2014 0.22 0.07 0.06 0.01 0.08
2013 0.02 0.03 0.21 0.16 0.09
2012 0.03 0.02 0.06 0.05 0.04
2011 0.09 0.03

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.